Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen

Area of Science:

• Oncology
• Pharmacology
• Immunotherapy

Background:

• Radiotherapy is a cornerstone in non-small cell lung cancer (NSCLC) treatment.
• Improving drug delivery and specificity of radiosensitizing agents remains a challenge.
• Antibody-drug conjugates (ADCs) offer a targeted approach to drug delivery.

Purpose of the Study:

• To develop and evaluate an antibody-drug conjugate (ADC) targeting the radiation-inducible antigen TIP1 on NSCLC cells.
• To assess the efficacy of a TIP1-targeting ADC in combination with radiotherapy.
• To improve the pharmacokinetics and cancer specificity of radiosensitizing drugs.

Main Methods:

• Prioritization of anti-TIP1 antibodies based on affinity, cancer-specific binding, and internalization.
• Conjugation of the lead antibody (7H5) with a radiosensitizing drug (MMAE) to create 7H5-VcMMAE.
• In vitro and in vivo studies evaluating cytotoxicity, radiosensitization, colony formation, and tumor growth in NSCLC models.

Main Results:

• The anti-TIP1 antibody 7H5 demonstrated high affinity and specific binding to TIP1 on NSCLC cells, with efficient endocytosis.
• 7H5-VcMMAE showed significant cytotoxicity and radiosensitizing effects on NSCLC cells in vitro.
• Combination therapy with 7H5-VcMMAE and radiation resulted in prolonged tumor growth delay and improved survival in preclinical NSCLC models.

Conclusions:

• Targeting radiation-inducible TIP1 with a radiosensitizing ADC is a promising strategy for enhancing NSCLC therapeutic efficacy.
• This novel ADC approach targeting radiation-inducible antigens holds potential for clinical application in NSCLC patients undergoing radiotherapy.
• Further clinical trials are warranted to validate this approach in lung cancer patients.